# VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

> **NCT03122730** · PHASE2 · COMPLETED · sponsor: **Aerogen Pharma Limited** · enrollment: 17 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **COMBINATION_PRODUCT:** VentaProst

## Key facts

- **NCT ID:** NCT03122730
- **Lead sponsor:** Aerogen Pharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2019-03-01
- **Final completion:** 2019-05-30
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03122730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03122730, "VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03122730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*